News

  • 20 February 2018

    Evolus reports positive Phase III data of prabotulinumtoxinA

    Evolus has reported positive data from a Phase III clinical trial evaluating prabotulinumtoxinA in comparison with onabotulinumtoxinA for the treatment of patients with glabellar lines, also known as ‘frown lines’...